ABUS
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Vancouver, British Columbia and has research facilities in Warminster, Pennsylvania.
Arbutus Biopharma Corporation (ABUS) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (F). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.4) | F (0.5) | B+ (3.8) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-11-10 | B (3.4) | F (0.2) | B+ (3.7) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-03 | B (3.4) | F (0.2) | B+ (3.7) | C+ (2.8) | C+ (2.7) | C+ (2.6) |
| 2026-10-27 | B (3.4) | F (0.2) | B+ (3.8) | B- (2.9) | C+ (2.6) | C+ (2.6) |
| 2026-10-20 | B (3.4) | F (0.2) | B+ (3.8) | C+ (2.8) | C+ (2.6) | C+ (2.6) |